BI-765179

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBI-765179
Drug Alias NameBI-765179
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-Tumor necrosis factor receptor superfamily member 9Anti-Prolyl endopeptidase FAP
TargetsTumor necrosis factor receptor superfamily member 9Prolyl endopeptidase FAP
Therapy Area/IndicationsSquamous Cell Carcinoma of Head and NeckNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[15] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim International GmbhLonza AG +[4] 
Inactive CompaniesN/A
Active IndicationsSquamous Cell Carcinoma of Head and NeckNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A